Senexin B manufacturer br Resource details br We generated K

Resource details
We generated KCL032 clinical grade hESC line following protocols, established previously (Ilic et al., 2012; Stephenson et al., 2012), and now adapted to cGMP conditions. The expression of the pluripotency markers was tested after freeze/thaw cycle (Fig. 1). Differentiation potential into three germ layers was verified in vitro (Fig. 2). Molecular karyotyping identified a novel 2.4Mb gain on chromosome 5p14.3, containing a single gene, CDH18 (Cadherin-18), that was also present in one of two sibling cell lines, KCL033, but not in KCL034, a third sibling. A duplication of this size has not been reported to date, but its presence in two sibling hESC lines strongly suggests that it was inherited from one of the parents rather than by acquisition during hESC derivation and culture (Canham et al., 2015). The 2498.8bp gain starts at bp 19,086,546 and ends at bp 21,585,311 as referred to Human Genome Build 38.
Materials and methods
Author disclosure statement
Acknowledgments This work was supported by the UK Medical Research Council grants G0701172 and G0801061. We thank Dr. Yacoub Khalaf, Director of the Assisted Conception Unit of Guy\'s and St. Thomas\' NHS Foundation Trust and his staff for supporting the research program. We are especially indebted to Prof. Peter Braude and to the patients who donated embryos.
Resource Table: G15.AO
Resource table
Resource details
Materials and methods
Verification and authentication
Resource table
Resource details Lymphoblast Senexin B manufacturer (CON8), derived from a 69-year-old individual (Brouwers et al. 2012) were reprogrammed employing oriP/EBNA-1-based episomal plasmids expressing OCT4, SOX2, KLF4, C-MYC, L-MYC, LIN28 and a p53 shRNA. Just clone B of Lymph8-iPS cell line was slightly positive for the episomal vector (at passage 10), clone A was negative for EBNA-1 and oriP but both clones were positive for the pluripotency-associated genes OCT4, SOX2, NANOG and TGDF1 (Fig. 1A). Pluripotency was confirmed by (i) expression of OCT4, SOX2, NANOG, TRA-1-60 and TRA-1-81 and SSEA4 (Fig. 1B) and (ii) embryoid body (EB)-based spontaneous differentiation into cell types representative of the three germ layers, namely ectoderm (Nestin), mesoderm (SMA — smooth muscle actin) and endoderm (AFP — α-feto protein) (Fig. 1C). The DNA fingerprint of Lymph8-iPS cell line was identical to the parental lymphoblast line CON8 (Fig.1D). Karyotype analysis was male (XY) and both lines exhibited a normal diploid chromosomal content (Fig. 1E). As depicted in the Dendrogram (Fig. 1F), the transcriptome of the parental lymphoblast cells is distinct from the pluripotent cell lines, Lymph8-iPS and the embryonic stem cell line H1, which cluster together with a Pearson correlation of 0.95.
Materials and methods
Acknowledgments JA acknowledges support from the Medical Faculty, Heinrich-Heine-University, Düsseldorf. Research at the Antwerp site is funded in part by the Belgian Science Policy Office Interuniversity Attraction Poles program (BELSPO, www.belspo.be) (IAP P7/16), the Flanders Impulse Program on Networks for Dementia Research (VIND) (IWT 135043) and the University of Antwerp Research Fund (http://www.uantwerpen.be/). JA, FS, KS and CVB are members of the EU project-AgedBrainSYSBIO. The AgedBrainSYSBIO project received funding from the European Union Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305299.
Resource table
Resource details
Materials and methods
Verification and authentication
Resource table
Resource details
We generated KCL016 clinical grade hESC line following protocols, established previously (Ilic et al., 2012; Stephenson et al., 2012). The expression of the pluripotency markers was tested after freeze/thaw cycle (Fig. 2). Differentiation potential into three germ layers was verified in vitro (Fig. 3).